12 results
This study aims to clarify whether the brain dopamine and noradrenaline system underlie the electrocortical responses (event-related potentials) that are sensitive to cues signalling reward and probability, the P200 and P300.
Primary objective:Plasma levels of clonidine, in order to describe pharmacokinetic and pharmacodynamic properties of intravenous clonidine in critically ill ventilated ICU patients.Secondary objectives are: * to evaluate the effect of a 3-hr loading…
To determine the beneficial effect of a single dose of 150 µg clonidine as an adjuvant to chirocaine in retrobulbar block.
The objective of the study is to investigate the effect of alfa2-adrenoceptors on bone turnover.
1) To study the effect of Clonidine on lumbar radicular pain with a transforaminal epidural injection after 1 week, 1, 3 and 6 months using a BPI.2) To study the effect of Clonidine on lumbar radicular pain with a transforaminal epidural injection…
The goal of the current investigation is to test the noradrenergic part of a new model that accounts better for results of pharmacological research. This model states that the cholinergic system underlies disengagement, and that the…
(1) To establish the pharmacokinetic profile of clonidine following oral administration in children with suspected GH deficiency. (2) To relate the pharmacokinetics of clonidine to the observed expected (GH-response, cortisol response, depth and…
The goal of the current investigation is to test a new model that accounts better for results of pharmacological research. This model states that the cholinergic system underlies disengagement, and that the noradrenergic system underlies bias. Two…
The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab in…
The primary objective of this study is to compare the efficacy of teclistamab monotherapy (Arm A) with that of an investigator*s choice of PVd or Kd (Arm B: termed PVd/Kd hereafter) as assessed by PFS.
Primary- Part 1: To identify recommended Phase 2 doses and schedules (RP2Ds) for each combination.- Part 2: To characterize the safety of each RP2D for each combinationSecondary- To characterize the pharmacokinetics and pharmacodynamics of each…